InSituBioprintingforWoundHealing

Why It Matters

Severe burns and chronic wounds affect millions globally, leading to significant pain, disfigurement, and high healthcare costs (e.g., $50 billion annually for chronic wounds in the US). In situ bioprinting could revolutionize wound care by enabling rapid, personalized, and scar-free regeneration of skin or other tissues directly at the point of injury, significantly improving patient outcomes and reducing hospital stays. Burn victims, chronic wound patients, and emergency healthcare providers win; traditional skin graft businesses might face disruption. Technical challenges include ensuring cell viability during printing, precise targeting and adhesion of printed cells to irregular wound beds, and managing infection risk in open wounds. Regulatory approval for a live-cell printing device would also be complex. First-in-human trials for simpler wounds could begin in 5-8 years, with widespread clinical adoption in 10-15 years. WFIRM (US) is a pioneer, alongside significant efforts in Canada and Europe. A second-order consequence is the potential for battlefield medicine to dramatically improve, allowing rapid on-site repair of severe injuries, fundamentally changing military medical logistics.